ProCE Banner Activity

CE / CME

State of the ART: Safety and Tolerability of HIV Treatments During Pregnancy

Multimedia

In this video module, learn from experts about special considerations when selecting ARV medications during pregnancy including efficacy, pharmacokinetic and safety data.

Pharmacists: 0.50 contact hour (0.05 CEUs)

Nurses: 0.50 Nursing contact hour

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: August 12, 2022

Expiration: August 11, 2023

No longer available for credit.

Share

Faculty

William R. Short

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine and Obstetrics and Gynecology
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Janssen Therapeutics, Division of Janssen Products, LP

ViiV Healthcare

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for patients with HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal first-line HIV regimens for individual patients, integrating safety and tolerability considerations alongside other important factors
  • Apply appropriate ART modification strategies for patients experiencing adverse events or poor tolerability while receiving a virologically suppressive regimen
  • Incorporate patient characteristics into ART strategies to optimize HIV care for special populations

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine and Obstetrics and Gynecology
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS: consultant/advisor/speaker: Janssen, ViiV.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer Blanchette, PhD, has no relevant financial relationships to disclose.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant financial relationships to disclose.

Jacqueline Meredith, PharmD, BCIDP

Scientific Director

Jacqueline Meredith, PharmD, BCIDP, has no relevant financial relationships to disclose.

Zachary Schwartz, MSc, ELS

Scientific Director

Zac Schwartz, MSc, ELS, has no relevant financial relationships to disclose.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-194-H02-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Additional Information

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 12, 2022, through August 11, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve learners’ competence in individualizing ART regimens for HIV by examining patient characteristics and the latest ART safety and tolerability data.